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T Cell-independent Antibody-mediated Clearance of  
Polyoma Virus in T Cell-deficient Mice 
By Eva Szomolanyi-Tsuda and Raymond M.Welsh 
From the Department of Pathology, University of Massachusetts Medical Center, Worcester, 
Massachusetts 01655 
Summary  
Polyomavirus (PyV) infection of SCID mice, which lack functional T and B cells, leads to a le- 
thal acute myeloproliferative disease (AMD) and to high levels of virus replication in several or- 
gans by two wk after infection. This is in contrast to infection o fT  cell-deficient athymic nude 
mice, which are resistant to acute PyV-induced disease and poorly replicate the virus in their 
organs. This major difference in the virus load and in the outcome of PyV infection between 
SCID and nude mice suggested that an efficient, T cell-independent antiviral mechanism oper- 
ates in T cell-deficient, PyV-infected mice. To investigate this possibility, mice with different 
genetically engineered T and/or B cell deficiencies and SCID mice adoptively reconstituted 
with B and/or T cells were infected with PyV. The results indicated that the presence of B cells 
in the absence of T cells protected mice from the AMD, and this was accompanied by a major 
reduction of PyV in all organs tested. Sera from PyV-infected T cell receptor (TCIK) e~[3 
knockout or TCR ot[3 ~/8 knockout mice contained IgG2a antibodies to PyV. Sera or purified 
immunoglobulin fractions from PyV-infected TCR oq3 knockout mice protected SCID mice 
from the PyV-induced AMD. To our knowledge, this is the first report of an effective T cell- 
independent antibody response clearing a virus and changing the outcome of infection from 
100% mortality to 100% survival. 
V irus-specific T cells usually play a major role in the process of recovery from acute virus infections (1). Af- 
ter an early phase of the infection, when nonspecific factors 
such as NK cells contribute to decreasing the virus load (2), 
MHC-restricted cytotoxic T cells locate and destroy virus- 
infected target cells. T cells also secrete cytokines, which 
further impair virus replication and participate in several as- 
pects of the immune response (3). For the generation of a 
high-affinity antibody response and for efficient isotype 
switching from IgM to IgG and IgA production, T cell 
help is believed to be essential (4--4). In some virus infec- 
tions, such as vesicular stomatitis virus (VSV) 1, reovirus, 
and Sindbis virus, humoral immunity in the presence of T 
cells can play a significant role in the control of infection 
(7-9). Of  interest is that athymic nude mice can clear in- 
tracerebral Sindbis virus infection similarly to immuno- 
competent mice, suggesting that a T cell-independent im- 
mune response may restrict he replication of this pathogen 
(10, 11). Nude mice, however, are not completely free of 
T cells, and a role for T cells or T cell-dependent antibod- 
ies could not be excluded in those experiments. Efficient 
1Abbreviations u ed in this paper." AMD, acute mydoproliferative disease; 
LCMV, lymphocytic choriomeningitis virus; PyV, polyomavirus; VSV, 
vesicular stomatis virus. 
control of an acute virus infection by antibodies produced 
in the absence o fT  cells has therefore not been shown. 
Recent developments in immunology, using mice with 
targeted isruption (knockout) of certain genes, show that 
there are many redundancies in the immune system. Mice 
defective in gene products shown to be important for con- 
trol of infections often can clear viruses or parasites with 
unexpected efficiency. For example, in mice defective in 
CD8 + T cells, virus infections known to be controlled by 
CD8 + CTL were cleared by compensating CD4 + T cells 
(12, 13). A potent anti-lymphocytic choriomeningitis virus 
(LCMV) T cell response and VSV clearance in IFN-~/re- 
ceptor knockout mice (14); detectable CTL responses to 
LCMV infection in IL-2 knockout mice (15), and the con- 
trol ofleishmaniasis in CD4 knockout mice (16) are further 
examples. This rePort shows that although T cells in the 
absence of B cells can provide full protection against polyo- 
mavirus (PyV) infection in mice, B cells can also clear PyV 
in a completely T cell-independent fashion, supporting the 
view that the immune system has components with over- 
lapping functions, and providing the first unambiguous ex- 
ample of a protective T cell-independent antiviral antibody 
response. 
PyV induces a lethal acute myeloproliferative disease 
(AMD) in SCID mice that lack functional T and B cells 
(17). This observation is surprising since hematological dis- 
orders are not part of the disease spectrum caused by PyV 
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infection in normal newborn or in T cell-deficient nude 
mice (18, 19). Moreover, the AMD in SCID mice is asso- 
ciated with high levels of  PyV replication on day 14 after 
infection in all major organs tested, whereas in nude mice 
virus replication cannot be detected in most organs at this 
time (17, 20, 21). This enhanced virus replication and vi- 
rus-induced pathology in SCID versus nude mice suggest 
that an alternative mechanism of  PyV clearance is operating 
in mice deficient in T cells. Here we demonstrate hat PyV 
infection induces virus-specific IgM and IgG production by 
B cells in the absence o fT  cell (and NK cell) help, and that 
this antibody response can clear PyV and protect T cell-  
deficient mice from the acute lethal myeloproliferative dis- 
ease caused by the virus. 
Materials and Methods 
Mice and Virus Infection. C57BL/6JSz SCID mice, 129 TCR 
c~13"y8-/- mice, which had a targeted isruption in their TCR 
13 and 8 genes (22) and therefore lacked functional cq3 and "y8 T 
cells, 129• Ix - / -  mice, which had no functional B 
cells (23), 129XC57BL/6 and BALB/c mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME). 129• TCR 
c~13-/- mice, which had a targeted isruption of the TCR c~ or 
13 gene (24), and therefore had no functional o~13 T cells, had been 
backcrossed three-to-four times to C57BL/6. The TCtL o~13-/- 
(initially from Drs. P. Mombaerts and S. Tonegawa, Massachu- 
setts Institute of Technology, Cambridge, MA) and C.B17 SCID 
mice were bred in the Department of Animal Medicine of the 
University of Massachusetts Medical Center, and were housed in 
microisolator cages in this facility. Mice to be infected were inoc- 
ulated intraperitoneaily with 2 • 105-2 • 106 50% tissue culture 
infectious dose (TCID50) of PyV strain A2, provided by Dr. 
Michele M. Fluck (Michigan State University, East Lansing, MI). 
In Vivo NK or T Cell Depletion. Mice with the C57BL/6 back- 
ground, which express the NKI.1 alloantigen, were depleted of 
NK cells by i.p. injection with 20-100 IX1 of previously deter- 
mined optimal dilutions of ammonium sulfate cuts of ascites 
preparations of a rnonoclonal antibody to NKI.1 (25). C.B17 
SCID mice and TCR ~13~/~-/- mice, which do not express the 
NKI.1 alloantigen, were depleted of NK cells by an i.p. injection 
of 10 IXl of antiserum to asialo GM1 (Wako Chemicals USA, 
Dallas, TX). The anti-NKl.1 or asialo GM1 injections were re- 
peated weekly. The effectiveness of NK cell depletion was tested 
by using splenocytes of the depleted mice in cytotoxicity assays 
with 51chromium-labeled conventional NK target cells (YAC-1) 
in vitro. 
CD4+ and CD8+ T cells were depleted in vivo by i.p. injec- 
tion of 80 txl of an ascites preparation of a rat anti-mouse CD4 
rnonoclonal ntibody (clone GK1.5 [26]), and of 150 Ixl of a 1:10 
dilution of an ascites preparation of a rat anti-mouse CD8 mono- 
clonal antibody (clone 2.43 [27]), respectively. The injections 
were repeated every 6-7 d. The effectiveness of depletion was 
tested by FACS | (Becton Dickinson Co., Mountain View, CA) 
staining of peripheral blood leukocytes of killed mice, and these 
samples were found to be 98-99% free of CD4 + and CD8 + T 
cells. 
Adoptive Transfer Experiments. Spleens harvested from mice 
were ground between the frosted ends of glass microscope slides; 
the resulting cell suspension was filtered through a nylon mesh 
and treated with 0.83% NH4C1 to remove erythrocytes. Cells 
prepared from two-to-three spleens (with or without in vitro T 
cell depletion) were suspended in 650 ILl PBS; 200 IXl of this 
spleen cell suspension per mouse was given intravenously into 
C.B17 SCID mice. The adoptive transfer of cells was performed 
1 d before the infection of the mice intraperitoneally with 2 • 
10 s TCIDs0 units of PyV strain A2. 
In Vitro T Cell Depletion. Depletion of CD4 + and CD8 + T 
cells in spleen cell preparations in vitro was performed by treating 
the cells with rat anti-mouse Thy-1 monoclonal antibody (clone 
J1J.10 rat ascites preparation [28]; l :50 dilution, 150 IXl/107 cells) 
on ice for 45 rain, washing them twice with PBS, adding 25 IXl/ 
107 cells of guinea pig serum as a complement source, and then 
incubating the cells for 10 min on ice and for 50 min at 37~ Fi- 
nally, the cells were washed twice and suspended in medium. 
Southern Blots. DNA was prepared from frozen organs (liver, 
lung, kidney, and spleen) following published protocols (29). 2-10 
Ixg of undigested DNA or DNA cut with EcoRI, which cuts the 
PyV genome once, was subjected to electrophoresis in 0.8% aga- 
rose gels, and transferred to nitrocellulose paper by vacuum blot- 
ting (30), or to nylon transfer membrane (Magna Charge; Micron 
Separations Inc., Westboro, MA) by capillary transfer. The DNA 
blot was then baked, prehybridized, hybridized, washed, and ex- 
posed to autoradiography as described (31). PyV strain A2 cloned 
in pAT153 plasmid was kindly provided by Dr. Michele M. Fluck, 
and it was 32p-labeled by random priming for use as a hybridiza- 
tion probe. 
Immunofluorescent Staining. NIH 3T3 clone A31 cells were 
seeded on microscope glass coverslips and infected with PyV 
strain A2. On day 3 after infection, the cells on the coverslips 
were fixed for 10 rain with a 1 : 1 mixture of ethanol and ethyl- 
ether, followed by 20 rain in 95% ethanol. Staining was per- 
formed in a humid chamber for 35 rain at room temperature with 
dilutions of sera from PvY-infected immunocompetent or cx13 
knockout mice or of normal (uninfected) mouse serum. The cov- 
erslips were subsequently rinsed with PBS and incubated for 35 
rain with FITC-labeled antibodies pecific for mouse IgM (IX 
chain), IgG (~/ chain) (Vector Laboratories, Inc., Burlingame, 
CA), IgG1, IgG2a, IgG2b, and IgG3 (Zymed Laboratories, Inc., 
San Francisco, CA). The coverslips were rinsed with PBS, 
mounted on microscope slides with 90% glycerol/10% PBS, and 
viewed by fluorescence microscopy. 
Purification of IgG from PyV-infected oefl Knockout Mouse Serum. 
A protein A-Sepharose CL-4B (Pharmacia Biotech, Piscataway, NJ) 
column was prepared according to the manufacturer's in tructions 
and washed with 0.1 M Tris-HC1, pH 8.0 (binding buffer). A 
0.5-ml sample of pooled serum harvested on day 14 after PyV in- 
fection of o~13 knockout mice was mixed with 50 p,1 I M Tris- 
HC1, pH 8.0, loaded on the column, and washed with binding 
buffer (10• column volume). The IgG fraction was eluted by 
0.1 M citric acid, pH 3.0. To preserve the activity of acid-labile 
IgG, each collected fraction (0.5 ml) was neutralized by the addi- 
tion of 50 IXl 1 M Tris-HC1, pH 9.0. The protein content of the 
fractions was determined by an OD 280 reading, and the PyV- 
specific IgG content by indirect fluorescent s aining. 
Results 
Outcome of PyV Infection in Mice Deficient in T and~or B 
Cells. We have shown that SCID mice developed a fatal 
AMD after infection with PyV. The incidence of the AMID 
(100%) and the survival time of  the SCID mice (14~16 d) was 
not influenced by the genetic background of  the mice or 
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Table 1. PyVoinduced Disease in Immunodeficient Mice 
Mice No. of mice Depletion (in vivo) Killed* (day) Disease 
C.B17 SCID 15 - 13.6 +- 0.5' AMD 
C57BL/6 SCID 22 - 13.9 + 1.3 AMD 
C.B17 SCID 5 ctAGM1 14.2 + 0.8 AMD 
C57BL/6 SCID 22 oLNKI.1 13.9 + 1.3 AMD 
TCR ~t13 - / -  3 - 28(1)~ GI 
69(1) GI 
87(1) Healthy 
TCR ct l3 - / -  4 otNKl.1 67(1) GI 
87(3) Healthy 
TCR ctl3~/8- / - 4 - 14(2) Healthy 
42(2) Healthy 
TCK ot13~/8-/- 5 otAGM1 14(2) Healthy 
42(3) Healthy 
I~- / - 3 - 110 (3) Healthy 
~- / -  3 otCD4/ctCD8 15.7 + 0.6 AMD 
Ix + / + 3 - 110 (3) Healthy 
Ix + / + 3 ctCD4/txCD8 110 (3) Healthy 
* Mice were killed healthy or moribund on the indicated ay. Moribund mice had ruffled fur, pale ear color, and hunched posture, and would be ex- 
pected to die within 24 h according to previous experiments. 
r deviation. 
~No. of mice. 
GI, gastrointestinal disease, 
by the presence or absence of  NK cells (17). The fact that 
this pathology was very different from the tumor induction 
described in nude mice indicated that B cells and/or ex- 
trathymically developing T cells might have an important 
role in PyV pathogenesis. To address this question, we in- 
fected mice having various T and/or B cell deficiencies 
with PyV (Table 1). 
Mice that had a targeted isruption in the TClk ot or 13 
gene (ct13 knockout mice) (24) survived the acute phase of  
PyV infection and did not show any symptoms of the 
AMD up until 3 mo after infection. Depletion of  the TClk 
or13 knockout mice of  NK  cells in vivo by anti-NKl.1 anti- 
bodies did not influence this outcome. Mice deficient in 
both 0tl3 and ~/g T cells (22) also survived, regardless of  the 
presence or absence of  NK  cells. Two of three ct13 knock- 
out mice and one of four NK-depleted ct13 knockout mice 
had to be killed between day 28 and 69 after infection, be- 
cause the animals had gastrointestinal obstruction or serious 
wasting associated with diarrhea. These symptoms were 
consistent with an ulcerative cohtishke pathology that is 
known to affect this mutant mouse strain (32). Therefore, 
we consider the death of these animals not PyV related. 
Mice deficient in functional B cells due to a targeted is- 
ruption of the Ig Ix chain gene ( Ix - / - )  (23) were also re- 
sistant o the PyV-induced acute myeloproliferation. How-  
ever, when these Ix - / -  mice were depleted in vivo of  
CD4 + and CD8 + T ceils by combined injections with anti- 
405 Tsuda and Welsh 
CD4 and anti-CD8 antibodies, the animals (three of  three) 
died of  AMD by day 16, similarly to SCID mice. Mice 
with functional B cells from the same genetic background 
did not show any sign of  PyV-induced disease, even when 
depleted of  CD4 + and CD8 + T cells. These experiments 
indicate that although T cells can provide resistance against 
PyV infection, even in the absence of B cells, if functional 
CD4 + and CD8 + T cells are not present, B cells can mount 
an effective antiviral response as a second line of  defense. 
Prevention of PyV-induced AMD by Adoptive Transfer of B 
Cells into SCID Mice. To further investigate the role of  
different cell populations of  the immune system in the re- 
sistance to PyV infection, adoptive transfer experiments 
were performed (Table 2). Spleen cells were prepared from 
uninfected, immunocompetent BALB/c mice. This cell 
population was used directly for adoptive transfer, or was 
first depleted o fT  cells in vitro by lysing the cells with anti- 
Thy-1 antibody and complement. The success of the de- 
pletion was monitored by FACS | staining. Splenocytes 
from ot13 T cell knockout mice, B cell knockout mice, and 
B cell knockout mice after T cell depletion were also used 
for adoptive transfer into SCID mice. Adoptive transfer of  
the total spleen cell population (T and B ceils) protected 
SCID mice not only from AMD, but from later tumor in- 
duction as well. All mice receiving B cells (Thy-l-depleted 
splenocytes, or spleen cells from ct13 knockout mice) were 
protected from the AMD, but in a fraction of  these ani- 
Table 2. Protection of C. B I 7 SCID Mice from Py V-induced Acute Disease by Adoptive Cell Transfer 
No. of Source of cells Depletion Cell No. 
mice transferred (in vitro) given Day Killed* Disease 
Exp. 1 2 C.B17 spleen ccThy-1 2.5 )< 107 96 Tumor (1)* 
Healthy (1) 
Exp. 2 3 C.B17 spleen - 108 105 Healthy (3) 
3 C.B17 spleen ~Thy-I 5 X 107 90 Hind leg 
Paralyzed (1) 
Healthy (2) 
3 TCP,, o t [3 - / -  - ND -~ 68 Tumors (2) 
68 Healthy (1) 
Exp. 3 4 Ix - / -  spleen otThy-I 1.1 X 10 (' 13.2 AMD (4) 
4 b~+/+ spleen otThy-1 3 • 107 82 Tumors (2) 
Healthy (2) 
*Mice were killed healthy or moribund on the indicated day. 
*No. of mice. 
~Cell number was not determined, cells prepared from three cq3 knockout mouse spleens were injected into three recipient SCID mice. 
mals, PyV infection induced multiple mammary tumors. 
This finding is consistent with published data showing a 
high frequency of  mammary tumors in female BALB/c 
nude mice (21). Four out of  four SCID mice that received 
adoptive transfer of  T cell-depleted splenocytes from B cell 
knockout mice died by day 14 with symptoms of  AMD, 
indicating the essential role orB  cells in protection when T 
cells were absent. 
Py V Replication in SCID Mice Reconstituted with B or B and 
T Cells. Whereas in immunocompetent or nude mice the 
PyV replication is not detectable in most major organs by 2 
wk after infection, in SCID mice high levels of  virus repli- 
cation have been observed at this time in all organs tested 
(17, 20). We asked whether the protection of  SCID mice 
from the AMD by B cells was associated with a major de- 
crease in the amount of  the virus in different organs. SCID 
mice, SCID mice adoptively transferred with B cells (Thy- 
1-depleted splenocytes) or with B and T cells (undepleted 
spleen cells) were infected with PyV and killed at days 3, 7, 
and 14 after infection. The presence of viral genome in 
DNA samples prepared from spleen, kidney, liver, and lung 
tissues of  the animals was analyzed by Southern blots, using 
cloned, 32p-labeled PyV A2 genome as the hybridization 
probe. At day 3, all three groups of  mice had viral signal in 
the spleen (Fig. 1 A). At this time DNA samples from other 
organs (kidney, lung, and liver) did not show the presence 
of  viral genome, even after a long exposure of the blots 
(kidney and lung not shown). At day 7, strong viral bands 
could be observed in all four organs in SCID mice, a find- 
ing consistent with our previous results (17). In SCID mice 
adoptively transferred with B cells alone, or with B and T 
cells, very little or no virus-specific DNA was detected in 
any of the organs tested. Even in the spleen the viral signal, 
which could be observed at day 3, was largely diminished 
by day 7 (Fig. 1 /3). At day 14, whereas PyV could be de- 
tected in all four organs in SCID mice, the virus signal was 
absent from SCID mice receiving B cells or T and B cells 
(Fig. 1 C and Fig. 2/3). The fact that we could not observe 
significant differences in the efficiency of  PyV clearance in 
the spleen, kidneys, liver, or lung by B cells alone or by T 
and B cells together at day 7 and 14 after infections indi- 
Figure 1. Effect of adoptive transfer of B and T cells on PyV replica- 
tion in spleen and liver of C.B17 SCID mice. Southern blots of DNA 
samples (5 I-~g) prepared from organs of SCID mice, SCID mice reconsti- 
tuted with Thy-l-depleted BALB/c spleen cells (SCID+B cells), and 
SCID mice reconstituted with spleen cells of BALB/c mice (SCID+ 
T+B cells) taken at different times after infection. The blots were probed 
with 32p-labeled cloned PyV genome. (A) Uncut DNA of spleens (lanes 
1-3) and livers (lanes 4-6) at day 4 after infection. SCID mice (lanes 1 
and 4), SCID+B cells (lanes 2 and 5), and SCID+T+B cells (lanes 3 and 
6). (/3) Day 7 postinfection EcoRI-cut DNA from spleens (lanes 1-3) and 
livers (lanes 4-6) ofSCID mice (lanes 1 and 4), SCID+B cells (lanes 2 
and 5), SCID+T+B cells (lanes 3 and 6). (C) Day 14 postinfection 
EcoRI-cut DNA from spleens (lanes 1-3) and livers (lanes 4-6) of SCID 
mice (lanes 1 and 4), SCID+B cells (lanes 2 and 5), SCID+T+B ceils 
(lanes 3 and 6). 
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Figure 2. Transfer ofserum from PyV-infected 
ct[3 knockout mice into C.B17 SCID mice causes 
major delay in PyV replication. (A) PyV-infected 
SCID mice treated with serum of PyV-infected 
tx[3 knockout mice; Southern blot of DNA sam- 
ples (1 p,g/lane) from spleen (la es 1, 5, 9, and 
15), kidney (2, 6, 10, and 16), liver (3, 7, 11, and 
17), and lung (4, 8, 12, and 18). Lanes 1-4: day 4 
after infection, lanes 5-8: day 13, lanes 9-13 and 
15-I8: day 32. Lane I4:0.1 ng pAT153-PyV A2 
plasmid DNA. (B) PyV-infected SCID mouse. 
Day 13 after infection. Lane 1: spleen, lane 2: 
kidney, lane 3: hver, and lane 4: lung. Probe: 
32p-labeled, cloned PyV A2 genome. 
cates that B cells could control PyV rephcation in these or- 
gans in the absence o fT  cells. 
Protection Against AMD Is Mediated by Serum. We tested 
whether serum from PyV-infected ct[3 knockout mice 
could transfer protection to SCID mice against PyV-induced 
AMD. ot[3 knockout mice and C57BL/6 mice were in- 
fected with PyV; 7 d after infection, the mice were bled 
and serum was harvested. C.B17 SCID mice were then i - 
jected with the sera 1 d before PyV infection. Sera from 
normal, uninfected mice were used as negative controls. 
Sera from PyV-infected C57BL/6 mice or ot[3 knockout 
mice prolonged the survival of  the SCID mice, regardless 
of  the route of  injection (i.p. or i.v.) (Table 3). Sera from 
uninfected mice did not have any effect on survival. The 
mice that received "PyV-immune" sera died between day 
37 and 48 after infection with the pathological signs of  
AMD. This indicates that a single injection of  serum could 
not completely prevent but could delay the lethal outcome 
by 3-4 wk; the same 3-4-wk delay in the onset of  AMD 
was observed when serum harvested at day 14 after PyV in- 
fection ofot[3 knockout mice was used (Table 4). The pro- 
longed survival was accompanied by a delay in the kinetics 
of  virus rephcation (Fig. 2). In SClD mice treated with day 
7 serum of PyV-infected ot[3 T cell-deficient mice, no viral 
DNA could be detected by Southern blots at day 4 and 14 
after PyV infection, although by this time in untreated 
SCID mice, high levels of  PyV replication could be ob- 
served in all organs tested. However, by day 32, the PyV 
genome became readily detectable in samples of  spleen, 
kidney, hver, and lung DNA from the PyV-immune se- 
rum-treated SCID mice (data from two individual mice are 
shown in Fig. 2). 
Serum of Py V-infected T Cell-deficient Mice Contains Virus- 
specific IgM and IgG. To determine whether serum derived 
from PyV-infected cx[3 knockout mice at day 14 after infec- 
tion contains PyV-specific IgM or IgG antibodies, indirect 
immunofluorescent staining experiments were performed. 
3T3 cells infected with PyV for 3 d were reacted with a 1:20 
dilution of  the serum, followed by staining with FITC-con- 
jugated murine IX chain- or murine y chain-specific second 
antibody. Bright nuclear fluorescent staining of  the PyV- 
infected cells could be observed with the y chain~specific 
reagent (Fig. 3 A). This staining was specific, because PyV- 
infected cells exposed to non-PyV- immune serum and the 
anti -y-FITC antibody exhibited only diffuse, cytoplasmic 
background fluorescence (Fig. 3 B.). Using PyV-immune 
ot13 knockout serum with FITC-antimurine Ix antibody, a 
virus-specific nuclear fluorescent signal was also observed, 
indicating that T cell-deficient mice mount virus-specific 
IgM and IgG responses against PyV. Immunofluorescent 
Table 3. Effect of Serum Transfer onthe Survival Time of Py V-infected C. B 17 SCID Mice 
No. of Source of serum Route of Killed* 
mice transferred Serum dose injection (day) Disease 
Exp. 1 3 Uninfected C57BL 500 ml i.p. 13.3 --- 0.6* AMD 
3 PyV-infected C57BL~ 500 ml i.p. 45 (3)11 AMD 
Exp. 2 1 Uninfected C57BL 100 + 250 Ixl i.v. + i.p. 15 (1) AMD 
2 PyV-infected TCR otl3 - / -~  100 + 250 Ixl i.v. + i.p. 40 (2) AMD 
Exp. 3 2 Uninfected C57BL 200 txl i.v. 14 (2) AMD 
2 PyV-infected C57BL~ 200 Ixl i.v. 37 (2) AMD 
2 PyV-infected TCR Ix[3-/-~ 200 txl i.v. 48 (2) AMD 
*Mice were killed moribund o  the indicated day. Moribund mice had milled fur, pale ear color, and hunched posture, and would be expected to 
die within 24 h according to our previous experiments. 
*Standard eviation. 
~Serum was harvested atday 7 after infection. 
IINumber of mice. 
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Table 4. Ig Fractions of PyV-infected c~ Knockout Mouse Serum Prolong the Survival of PyV-infected C.B17 SCID Mice 
No. of Mice* Serum given (i.v.) Volume Titer* Time of deaths 
/xl d 
Exp. 1 2 None - -  - -  16,17 
2 Naive ix[3 knockout serum 150 ND 15,18 
2 Naive normal mouse serum 100 ND 16,17 
2 PyV-infected, ot[3 knockout serumEI 100 ND 39 +82 
2 Peak I** 200 < 1:20 20,21 
2 Peak I** 450 <1:20'* 21,21 
2 Peak llg~ 200 1:20 19,21 
Exp. 2 2 None - -  - -  13,13 
2 PBS 100 - -  15,17 
2 PyV-infected, ot[3 knockout serumll 100 1:800 39,48 
2 IgG fr.41111 100 1:200 33,41 
2 IgG fr.51111 150 1:80 36,40 
*Mice were injected with l0 s TCIDs0 of PyV strain A2 i.p. on the day ofi.v, serum injections. 
*Titer defined as the highest dilution of serum resulting in positive immunofluorescence of PyV-infected 3T3 cells with an IgG-specific FITC- 
labeled second antibody. 
SMice were killed moribund on the indicated ay (see footnote to Tables 1 and 3). 
ItSemm was harvested on day 14 after infection. 
82 mouse died on day 39, the other was killed with no symptoms. 
**Peak I chromatography fraction contained both IgM and IgG. 
**Peak I fraction showed positive IgG-specific fluroescence undiluted, but in 1:20 dilution was negative. 
~Peak II chromatography fraction contained only IgG. 
ImlgG-containing fractions of ot[3 knockout mouse serum harvested 14 d after PyV infection were obtained by chromatography on a protein 
A-Sepharose column (see Materials and Methods). 
staining of  PyV-infected 3T3 cells with serum of  PyV- 
infected ot[3 knockout mice (1:20 dilution) and F ITC-  
labeled second antibodies pecific for subclasses of  IgG re- 
vealed that the serum of PyV-infected ot[3 knockout mice 
contained predominantly IgG2a, as IgGl - ,  IgG2b-, and 
IgG3-specific staining was not detectable. However, bright 
nuclear fluorescence was observed with the anti- IgG2a- 
F ITC antibody. Sera from PyV-infected, NK-depleted 
oL[3~/8 knockout mice harvested 2 wk after infection also 
contained levels of  IgG2a comparable to those of  the PyV- 
infected cx[3 knockout mouse serum. Staining with a 1:100 
dilution of  this sera and IgG2a-specific FITC-labeled anti- 
bodies resulted in bright nuclear fluorescence of PyV-infected 
cells (not shown). 
To test whether purified IgM or IgG fractions of  PyV- 
infected ot[3 knockout mice can protect SCID mice against 
the acute PyV-induced disease, the serum was fractionated 
by chromatography on a Sephacryl 300 (Pharmacia Bio- 
tech, Uppsala, Sweden) column. The first protein peak 
eluted from the column was enriched for IgM, but con- 
tained IgG as well. The second protein peak contained 
IgG, but no detectable IgM. SCID mice injected with 200 lxl 
of either fraction survived PyV infection significantly longer 
than SCID mice treated with sera of  naive knockout mice 
before infection (Table 4, Exp. 1). In a second experiment, 
high titer antiviral IgG was purified by protein A-Sepharose 
chromatography from the serum of 0t[3 knockout mice har- 
vested on day 14 after infection. C.B17 SCID mice were 
injected intravenously with unfractionated PyV-infected 
ci[3 knockout serum (titer 1:800) and the peak IgG fractions 
fr.4 and ft.5 (titer 1:200 and 1:80, respectively) (Table 4, 
Exp. 2). Whereas all the mice without serum or IgG treat- 
ment died by day 17 (mean survival time 14.5 + 1.9), mice 
that received the purified IgG fractions from PyV-infected 
ot[3 knockout mouse serum survived 19-27 d longer. Fur- 
thermore, this survival time was very similar to that of  mice 
injected with unfractionated PyV-infected cl[3 knockout 
mouse serum, indicating that IgG produced in the absence 
of  T cells expressing ot[3 TCR provides protection against 
the lethal outcome of  PyV infection (Table 4). 
Discussion 
We show here that B cells in the absence of  T cells pro- 
tect mice from PyV-induced lethal AMD. This protection 
is mediated by the induction of  PyV-specific IgM and IgG 
antibodies, predominantly IgG2a, produced without any T 
cell help. These antibodies then dear PyV in different or- 
gans of  the PyV-infected mice. To our knowledge, this is 
the first example of a completely T ceLl-independent anti- 
body response ffectively reducing virus load ("clearance") 
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and thereby dramatically changing the outcome of a virus 
infection (from 100% lethality by day 16 to 100% survival). 
It is well known that virus-specific antibodies can pre- 
vent infection or reinfection by neutralization (33), and 
several studies have indicated that antibodies are also capa- 
ble of mediating virus clearance in vivo. Examples of this 
are reovirus and Sindbis virus clearance in the central ner- 
vous system of neonatal or SCID mice by the injection of 
monoclonal antibodies (8, 34), or influenza virus clearance 
by transfer of monoclonal antibodies into SCID mice (35). 
However, the generation of an efficient, high-affinity anti- 
body response and the switching from IgM to IgG or IgA 
production usually requires T cell help (4, 5). It is very in- 
teresting therefore, that PyV is an inducer of a protective 
antibody response in T cell-deficient mice. In PyV- 
infected SCID mice, the virus replicates to high levels, and 
the high level of virus antigens might be an important re- 
quirement for triggering T cell-independent antibody pro- 
duction. This is also suggested by a recent publication by 
Freer et al. (36), which reported induction of VSV-specific 
IgG in nude mice. In that system, the T cell dependence of 
both IgG and, to a lesser degree, IgN1, seemed to be depen- 
dent on the antigen dose, and only at very high antigen 
levels of UV-inactivated VSV was an "inefficient but sig- 
nificant" switch to IgG synthesis observed. However, since 
nude mice are not completely free o fT  cells, the possibility 
of helper factors produced by the remaining T cells was not 
excluded in those experiments. 
It is interesting to speculate which factors might contrib- 
ute to the efficient switch from IgM to lgG production in 
the absence of any T cell help (and even in the absence of 
NK cells) in the case of PyV infection. One factor in over- 
coming the lack of usual helper functions might be a char- 
acteristic feature of the antigen. The major capsid glyco- 
protein PyV, VP1, is repeated periodically 360 times (in 72 
pentamers) in the virion capsid structure (37, 38). T cell- 
independent antigens typically consist of multiple repeating 
epitopes that allow for extensive cross-linking of the anti- 
gen receptor on the B cell surface. Most T cell-indepen- 
dent antigens are polysaccharides, but polymeric protein 
structures with repetitive pitopes, such as bacterial flagellin, 
can be T cell-independent antigens as well (39, 40). There- 
fore, the structural periodicity of the PyV virion capsids 
might be responsible, at least in part, for the ability to trig- 
409 Tsuda and Welsh 
Figure 3. Serum from PyV-infected 
etl3 knockout mice ontains PyV-spe- 
cific IgG. Staining of PyV-infected 
cells with (A) 1:20 dilution of serum 
from PyV-infected etl3 knockout mice 
and FITC-labeled antibody specific for 
mouse IgG "y chain. Strong nuclear 
fluorescence of PyV-infected cells in- 
dicates the presence of PyV-specific 
IgG in the serum. (B) 1:20 dilution of 
serum from uninfected mice and 
FITC-labeled mouse IgG ~/ chain- 
specific antibody. Only weak cytoplas- 
mic background staining can be ob- 
served. 
ger T cell-independent antibody responses. This idea is 
supported by a report by Bachmann et al. (41), which de- 
scribes that transgenic mice tolerant o nonrepetitive VSV 
glycoprotein antigen produced antibodies in response to 
the highly organized, repetitive form of the same antigen 
represented by formalin-inactivated virions. Therefore, the 
organization and density of antigenic epitopes had an im- 
portant role in determining B cell induction. However, 
since many viruses have capsids with similar (icosahedral) 
repetitive structures, it is surprising that T cell-independent 
antibody responses influencing the pathogenesis of other 
virus infections have not been reported so far. The newly 
available mouse strains with complete and selective T cell 
deficiencies will be useful for determining how widespread 
this phenomenon is. Other factors in PyV-infected T cell- 
deficient mice, such as the production of cytokines, may 
also contribute to the induction of a strong T cell-indepen- 
dent antibody response. 
Because the serum from PyV-infected 0tl3 knockout 
mice has some neutralizing activity in vitro (preliminary 
data, not shown), neutralization of PyV would be an obvi- 
ous mechanism of action of the antiviral antibodies. How- 
ever, the protective ffects of antibodies in vivo do not 
necessarily correlate with their in vitro neutralizing abilities 
(42--44). Both neutralizing and nonneutralizing antibodies 
can clear Sindbis virus in the infected central nervous sys- 
tem. In this case, viral protein synthesis and virus assembly 
are inhibited by the antibodies, which bind to the mem- 
brane of the virus-infected cells (8). In LCMV infection, 
reduction of viral titers in tissues is mediated by some, but 
not all neutrahzing antibodies. It is interesting to note that 
antibodies with IgG2a isotype are the best at protecting 
against LCMV (43), and that this isotype was shown to be a 
major component in the sera ofPyV-infected, T cell-deficient 
mice. IgG2a is known to be predominantly produced in re- 
sponse to virus infections in general, and to PyV infection 
in particular, in immunocompetent mice (45). It is surpris- 
ing, however, that this happens even in the absence of T 
cells after PyV infection. 
In summary, our results how that PyV can behave as a T 
cell-independent antigen and provide the first unambigous 
example we know of a virus inducing a physiologically rel- 
evant, T cell-independent antibody response that can con- 
trol the infection. 
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